Jason Rhodes
InvestorPartner at Atlas Venture · Board director at Dyne Therapeutics · Board director at Generation Bio · Board director at Gemini Therapeutics
Cambridge, Massachusetts, United States
Writes $500K – $5M checks · typically $2M
Find your path to Jason
117 people in our graph share verified history with Jason — schools, employers, funds. One of them is your warm intro.
About
Jason Rhodes is a partner at Atlas Venture focused on creating and building therapeutics companies. He was the founding CEO of Dyne Therapeutics and Rectify Pharmaceuticals and founding CEO of Disarm Therapeutics (acquired by Eli Lilly), and previously held leadership roles at Alnylam Pharmaceuticals and Epizyme. Earlier he was a founder and partner at Fidelity Biosciences (now F-Prime Capital), where he led therapeutics investments. He holds a BA from Yale University and an MBA from the Wharton School.
Contact· self-published, not guessed
Invests in
Biotech
Board director at Dyne Therapeutics
Intro paths
In turn, Jason can intro founders to Dyne Therapeutics's investors below.
Dyne Therapeutics's investors · 6
Co-founders at Dyne Therapeutics
Board director at Generation Bio
Intro paths
In turn, Jason can intro founders to Generation Bio's investors below.
Board director at Gemini Therapeutics
Intro paths
In turn, Jason can intro founders to Gemini Therapeutics's investors below.
Experience
- American Academy in RomeTrusteecurrent2026 — present
- Atlas VenturePartnercurrent2014 — presentCambridge, MA
- Rectify PharmaExecutive Chair (and founding CEO)current2020 — present
- Dyne TherapeuticsChairman (and founding CEO)current2017 — presentCambridge, MA
- Berklee College of MusicPresidential Advisory Council, Member2009 — 2022
- Disarm Therapeutics (acquired by Lilly in 2020)Chairman (and founding CEO)2016 — 2020
- EpizymePresident and CFO2010 — 2014NASDAQ: EPZM www.epizyme.com
- AlnylamVice President, Business Development2007 — 2010
- Fidelity Biosciences(F-Prime)Partner2001 — 2007
Skills & more
+12 more
OncologyMergersPrivate EquityDrug DiscoveryLifesciencesTechnology TransferPharmaceutical IndustryCommercializationBusiness DevelopmentStrategic AlliancesProduct DevelopmentProduct ManagementFrom Jason's professional profile.
Investments
Led
FoldRx
Board seats
AAVantgarde BioAccent TherapeuticsDisarm TherapeuticsDyne TherapeuticsK36 TherapeuticsKaryoVerseMithrilRectify PharmaceuticalsWeaver
Investor
AAVantgarde BioAccent TherapeuticsBE BiopharmaDisarm TherapeuticsGemini TherapeuticsGeneration BioK36 TherapeuticsRaze TherapeuticsRectify PharmaceuticalsReplimune GroupThird Harmonic Bio
Sources: the firm's website · curated public sources.
Colleagues at Atlas Venture
Network5
Investors connected to Jason in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Jason Rhodes?
- Jason Rhodes is a partner at Atlas Venture focused on creating and building therapeutics companies. He was the founding CEO of Dyne Therapeutics and Rectify Pharmaceuticals and founding CEO of Disarm Therapeutics (acquired by Eli Lilly), and previously held leadership roles at Alnylam Pharmaceuticals and Epizyme. Earlier he was a founder and partner at Fidelity Biosciences (now F-Prime Capital), where he led therapeutics investments. He holds a BA from Yale University and an MBA from the Wharton School.
- Where does Jason Rhodes work?
- Jason Rhodes is Partner at Atlas Venture and Board director at Dyne Therapeutics and Board director at Generation Bio and Board director at Gemini Therapeutics.
- What does Jason Rhodes invest in?
- Jason Rhodes invests in Biotech.
- What check size does Jason Rhodes write?
- Jason Rhodes typically writes checks of $500K – $5M.
- What boards does Jason Rhodes sit on?
- Jason Rhodes holds tracked board seats at AAVantgarde Bio, Accent Therapeutics, Disarm Therapeutics, Dyne Therapeutics, K36 Therapeutics, KaryoVerse, Mithril, Rectify Pharmaceuticals, Weaver.
- What companies has Jason Rhodes invested in?
- Investments tracked here include FoldRx, AAVantgarde Bio, Accent Therapeutics, BE Biopharma, Disarm Therapeutics, Gemini Therapeutics, Generation Bio, K36 Therapeutics, Raze Therapeutics, Rectify Pharmaceuticals, Replimune Group, Third Harmonic Bio.
- Where did Jason Rhodes go to school?
- Jason Rhodes studied at Yale University (BA, History - modern diplomatic and financial history); The Wharton School (MBA).
- Does Jason Rhodes lead rounds?
- Yes — Jason Rhodes has led 1 tracked investment.
Founder mafias
The Wharton School mafia570
Also came through, then founded or led a company.
+ 563 more
Yale University mafia373
Also came through, then founded or led a company.
+ 366 more
Atlas Venture mafia21
Also came through, then founded or led a company.
+ 14 more
Alnylam mafia4
Also came through, then founded or led a company.
Dyne Therapeutics mafia4
Also came through, then founded or led a company.
Same school
Also attended Yale University1,064
+ 1,058 more
Also attended The Wharton School2,000
+ 1,994 more
Shared employers
Also worked at American Academy in Rome1
Also worked at Rectify Pharma5
Also worked at Dyne Therapeutics6
Also worked at Berklee College of Music8
+ 2 more